Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation

Acute graft-versus-host disease (aGVHD) and cytomegalovirus reactivation are important complications after allogeneic stem cell transplantation (alloHSCT). Here, we evaluated the impact of treatment with alemtuzumab on the occurrence of aGVHD, cytomegalovirus reactivation and survival after alloHSCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Resende, C.B., Rezende, B.M., Bernardes, P.T.T., Teixeira, G.M., Teixeira, M.M., Pinho, V., Bittencourt, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2017
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343562/
https://www.ncbi.nlm.nih.gov/pubmed/28198910
http://dx.doi.org/10.1590/1414-431X20165566

Ejemplares similares

Ejemplares similares